Astellas Pharma is a global pharmaceutical company headquartered in Japan, dedicated to researching, developing, and manufacturing innovative medicines. With a strong focus on patient health, Astellas actively engages in pioneering therapeutic areas such as oncology, immunology, and cell and gene therapies.
Date confirmed from the Tokyo Stock Exchange (JPX) announcement schedule.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Astellas Pharma is scheduled to report its next quarterly earnings on 11/04/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Astellas Pharma last reported quarterly earnings on 8/5/2026 (Q2 2026). Earnings per share (EPS) came in at 79.15 JPY.
Across its last 5 earnings reports, Astellas Pharma stock moved by ±1.5% on average the following day. The largest reaction was -3.3% on 04/27/2026; 3 of 5 reactions were positive.
Astellas Pharma has beaten analyst EPS estimates in 4 of its last 5 evaluated quarters (beat rate: 80%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 5 report dates (close to close).
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.